Primecap Management Co. CA Purchases 22,600 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Primecap Management Co. CA increased its position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 1.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,520,630 shares of the company’s stock after purchasing an additional 22,600 shares during the period. Primecap Management Co. CA owned 2.13% of Zentalis Pharmaceuticals worth $4,608,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Zentalis Pharmaceuticals by 50.6% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 345,039 shares of the company’s stock valued at $1,045,000 after acquiring an additional 115,901 shares in the last quarter. Meriwether Wealth & Planning LLC purchased a new position in Zentalis Pharmaceuticals in the 4th quarter worth approximately $66,000. Raymond James Financial Inc. purchased a new position in Zentalis Pharmaceuticals in the 4th quarter worth approximately $68,000. Charles Schwab Investment Management Inc. boosted its stake in Zentalis Pharmaceuticals by 22.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 497,362 shares of the company’s stock worth $1,507,000 after purchasing an additional 91,152 shares during the period. Finally, Anfield Capital Management LLC grew its holdings in Zentalis Pharmaceuticals by 100.0% during the 4th quarter. Anfield Capital Management LLC now owns 129,318 shares of the company’s stock valued at $392,000 after buying an additional 64,659 shares in the last quarter.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. UBS Group lowered their target price on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Wedbush reiterated a “neutral” rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Wells Fargo & Company cut their price objective on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a research report on Monday. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $8.24.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ ZNTL opened at $1.79 on Thursday. Zentalis Pharmaceuticals, Inc. has a 1-year low of $1.61 and a 1-year high of $16.27. The business’s 50 day moving average is $2.14 and its two-hundred day moving average is $2.92. The stock has a market capitalization of $127.56 million, a P/E ratio of -0.72 and a beta of 1.75.

Insider Transactions at Zentalis Pharmaceuticals

In other news, insider Ingmar Bruns acquired 20,000 shares of the firm’s stock in a transaction on Thursday, February 6th. The stock was acquired at an average price of $2.28 per share, with a total value of $45,600.00. Following the completion of the purchase, the insider now directly owns 36,629 shares in the company, valued at approximately $83,514.12. This trade represents a 120.27 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jan Skvarka bought 60,000 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were acquired at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the purchase, the director now owns 149,551 shares of the company’s stock, valued at approximately $257,227.72. The trade was a 67.00 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 3.60% of the company’s stock.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.